^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CLBR001/SWI019
i
Other names: CLBR001/SWI019, switchable-CAR-T-cell-therapy, CLBR001 + SWI019, CLBR 001/SWI 019, CLBR-001/SWI-019
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AbbVie, Scripps Research Institute
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
16d
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (clinicaltrials.gov)
P1, N=16, Completed, Calibr, a division of Scripps Research | N=36 --> 16 | Trial completion date: Aug 2036 --> Oct 2025 | Trial primary completion date: Aug 2036 --> Oct 2025 | Enrolling by invitation --> Completed
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
CLBR001/SWI019
2ms
A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases (clinicaltrials.gov)
P1, N=0, Withdrawn, Calibr, a division of Scripps Research | N=12 --> 0 | Trial completion date: Aug 2028 --> Mar 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2028 --> Mar 2026
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
|
cyclophosphamide • CLBR001/SWI019
4ms
A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Calibr, a division of Scripps Research | Initiation date: May 2025 --> Feb 2026
Trial initiation date
|
cyclophosphamide • CLBR001/SWI019
1year
A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases (clinicaltrials.gov)
P1, N=12, Not yet recruiting, Calibr, a division of Scripps Research
New P1 trial
|
cyclophosphamide • CLBR001/SWI019
over1year
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=18, Completed, Calibr, a division of Scripps Research | Active, not recruiting --> Completed
Trial completion
|
CLBR001/SWI019
2years
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Calibr, a division of Scripps Research | N=36 --> 18 | Trial primary completion date: Aug 2023 --> Apr 2024
Enrollment change • Trial primary completion date
|
CLBR001/SWI019
almost3years
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=36, Active, not recruiting, Calibr, a division of Scripps Research | Recruiting --> Active, not recruiting
Enrollment closed
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
CLBR001/SWI019
over4years
First in Human Study of an on/Off Switchable CAR-T Cell Platform Targeting CD19 for B Cell Malignancies (CLBR001 + SWI019) (ASH 2021)
Following cyclophosphamide and fludarabine lymphodepletion, patients receive a single dose of CLBR001 cells, followed by daily infusion of SWI019 for 7 days...This event subsided within 24 hours of administration of dexamethasone with no recurrence of CRS observed with continued administration of a reduced dose (50%) of SWI109, providing support for the tunability of the platform...Accrual is ongoing in dose expansion cohorts of both CLBR001 cells and SWI019 switch. Updated results will be presented at the meeting.
P1 data • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
cyclophosphamide • dexamethasone • fludarabine IV • CLBR001/SWI019
over5years
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=36, Recruiting, Calibr, a division of Scripps Research | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
CD19 (CD19 Molecule) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
CLBR001/SWI019
Share via
